Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Compare the Safety and Efficacy of 177Lu-DOTATATE and Octreotide LAR in Unresectable or Metastatic, Progressive, Well-differentiated(G1 and G2) and SSTR-positive Adult GEP-NEN

NCT07057622 is registered in ClinicalTrials.gov with HTA Co., Ltd. as lead sponsor.

NCT NCT07057622
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07057622 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Compare the Safety and Efficacy of 177Lu-DOTATATE and Octreotide LAR in Unresectable or Metastatic, Progressive, Well-differentiated(G1 and G2) and SSTR-positive Adult GEP-NEN
Lead sponsor
HTA Co., Ltd.
Phase
Phase 3
Overall status
Recruiting
Start date
December 12, 2023
Completion date
February 24, 2027
Enrollment
184 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

nets ga68 lu177